Prasugrel: all 112 studies that test it

Page 1 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.RecruitingNCT07582835Phase 3
• Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 MonthsRecruitingNCT07507500Phase 4
• Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)RecruitingNCT07025148Phase 4
• Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)RecruitingNCT06916520Phase 4
• Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) StudyRecruitingNCT06821191Phase 4
• Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 InhibitorsRecruitingNCT06691191Phase 4
• Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured AneurysmRecruitingNCT05359224Phase 4
• Clopidogrel Monotherapy in Patients With High Bleeding RiskCompletedNCT05223335Phase 4Results posted
• Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)CompletedNCT03672097Phase 4Results posted
• Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation StudyCompletedNCT03489863Phase 4Results posted
• P3AMI Antiplatelet TrialCompletedNCT02376283Phase 4Results posted
• Pharmacological Effects of Crushing Prasugrel in STEMI PatientsCompletedNCT02212028Phase 4Results posted
• Prasugrel and Ticagrelor in ST-segment Elevation Myocardial InfarctionTerminatedNCT02075125Phase 3Results posted
• Cangrelor to Clopidogrel or Prasugrel Transition StudyCompletedNCT01979445Phase 2Results posted
• Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in DiabetesCompletedNCT01852214Not applicableResults posted
• Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery DiseaseCompletedNCT01852175Not applicableResults posted
• Cangrelor Prasugrel Transition StudyCompletedNCT01852019Phase 2Results posted
• A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)TerminatedNCT01794000Phase 3Results posted
• Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin CessationCompletedNCT01789814Phase 4Results posted
• Platelet Inhibition in Patients With Systolic Heart FailureCompletedNCT01765400Phase 4Results posted
• A Study of Prasugrel in Healthy ParticipantsCompletedNCT01648790Phase 1Results posted
• Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)TerminatedNCT01612884Phase 4Results posted
• Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)CompletedNCT01597375Phase 2Results posted
• Study of Prasugrel in Korean Healthy Male VolunteersCompletedNCT01591317Phase 1Results posted
• Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery DiseaseCompletedNCT01587651Phase 4Results posted
• Prasugrel for Prevention of Early Saphenous Vein Graft ThrombosisCompletedNCT01560780Phase 3Results posted
• Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI RegistryCompletedNCT01515345Phase 3Results posted
• A Study of Prasugrel in Pediatric Participants With Sickle Cell DiseaseCompletedNCT01476696Phase 2Results posted
• Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) StudyTerminatedNCT01452152Phase 4Results posted
• A Relative Bioavailability Study of a Prasugrel Orally Disintegrating TabletCompletedNCT01430091Phase 1Results posted
• The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery DiseaseCompletedNCT01260584Phase 4Results posted
• Prasugrel Re-load StrategiesCompletedNCT01201772Phase 4Results posted
• An Assessment of Prasugrel on Healthy Adults and Sickle Cell AdultsCompletedNCT01178099Phase 1Results posted
• Prasugrel Versus Placebo in Adult Sickle Cell DiseaseCompletedNCT01167023Phase 2Results posted
• Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery DiseaseCompletedNCT01107925Phase 1Results posted
• Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery DiseaseCompletedNCT01107912Phase 1Results posted
• Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary SyndromesTerminatedNCT01107899Phase 1Results posted
• A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial InfarctionCompletedNCT01015287Phase 3Results posted
• Prasugrel/Clopidogrel Maintenance Dose Washout StudyCompletedNCT01014624Phase 4Results posted
• The Dual Antiplatelet Therapy Study (DAPT Study)CompletedNCT00977938Phase 4Results posted
• CYPRESS - CYPHER for Evaluating Sustained SafetyStatus unknownNCT00954707Phase 4Results posted
• Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)TerminatedNCT00910299Phase 2Results posted
• A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary SyndromeCompletedNCT00830960Phase 3Results posted
• A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome SubjectsCompletedNCT00699998Phase 3Results posted
• Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)CompletedNCT00642174Phase 2Results posted
• The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)CompletedNCT00385944Phase 2Results posted
• Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With StentingCompletedNCT00357968Phase 2Results posted
• Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac EventCompletedNCT00356135Phase 2Results posted
• A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary InterventionCompletedNCT00097591Phase 3Results posted
• A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)CompletedNCT00059215Phase 2Results posted
• Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised StudyCompletedNCT05643586Phase 4
• Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or PrasugrelCompletedNCT05247385Phase 4
• Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary SyndromeCompletedNCT05183178Phase 4
• Optical Coherence Tomography-Guided PCI With Single-Antiplatelet TherapyCompletedNCT04766437Phase 2
• Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)Status unknownNCT04734353Phase 4
• Prasugrel in Severe COVID-19 PneumoniaStatus unknownNCT04445623Phase 3
• Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial AneurysmCompletedNCT03581409Phase 4
• Prasugrel vs. Ticagrelor on Myocardial Injury in STEMICompletedNCT03435133Not applicable
• A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy SubjectsCompletedNCT03430661Phase 1
• Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial InfarctionCompletedNCT03387826Phase 4
• CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCICompletedNCT03296540Phase 4
• Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV PatientsTerminatedNCT03054207Phase 1
• A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP ResponseWithdrawnNCT03027934Phase 4
• Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)CompletedNCT02944123Phase 3
• Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial InfarctionCompletedNCT02808767Phase 4
• Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary InterventionTerminatedNCT02548611Phase 4
• Ticagrelor vs. Prasugrel Effects on Infarct SizeWithdrawnNCT02507323Phase 2
• Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary StentingCompletedNCT02487732Phase 4
• Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtientsWithdrawnNCT02302508Phase 4
• High "on Treatment" Platelet Reactivity in the Intensive Care UnitStatus unknownNCT02285751Phase 2
• Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to ThrombolysisCompletedNCT02215993Phase 4
• Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)CompletedNCT02193971Phase 4
• Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy VolunteersStatus unknownNCT02075268Phase 1
• Prasugrel With Lower Dose - Loading DoseCompletedNCT02070159Phase 3
• A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding RiskCompletedNCT02044146Phase 2/3
• Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery DiseaseCompletedNCT01957540Phase 4
• Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary SyndromeCompletedNCT01951001Phase 4
• PKPD Study of Ticagrelor and Prasugrel in Healthy Korean MalesCompletedNCT01876797Phase 1
• Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With TicagrelorStatus unknownNCT01869309Phase 4
• High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)CompletedNCT01835353Phase 3
• Rapid Activity of Platelet Inhibitor Drugs Study 2CompletedNCT01805570Phase 4
• Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary SyndromeStatus unknownNCT01778842Phase 3
• The Elderly ACS II TrialCompletedNCT01777503Phase 4
• Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary SyndromeCompletedNCT01774838Phase 3
• Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor StudyCompletedNCT01700322Phase 4
• PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic VariantsCompletedNCT01641510Phase 3
• Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary InterventionCompletedNCT01609647Phase 3
• High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable PatientsCompletedNCT01543932Phase 3
• PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes MellitusCompletedNCT01531114Phase 3
• Rapid Activity of Platelet Inhibitor Drugs StudyCompletedNCT01510171Phase 4
• Prasugrel Versus Clopidogrel to TREAT High Platelet ReactivityCompletedNCT01493999Phase 4
• Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE TrialCompletedNCT01465828Phase 3
• Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)CompletedNCT01463150Phase 4
• Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function TestingStatus unknownNCT01456364Phase 4
• Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)CompletedNCT01452139Phase 2/3
• The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of ClopidogrelCompletedNCT01365221Phase 4
• Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy VolunteersCompletedNCT01346800Phase 1
• Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary InterventionTerminatedNCT01339026Phase 4
• Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)CompletedNCT01338909Phase 3
• Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOseCompletedNCT01336348Phase 3

← Prasugrel overview